Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 30;14(7):3887-3891.
doi: 10.21037/tcr-2025-782. Epub 2025 Jul 25.

First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn

Dena Hasan  1 , J Chad Brenner  1   2   3 , Paul L Swiecicki  2   4 , Molly E Heft Neal  1   2
Affiliations
Editorial

First-line therapy for recurrent metastatic head and neck squamous cell carcinoma: every rose has its thorn

Dena Hasan et al. Transl Cancer Res. .
No abstract available

Keywords: Head and neck squamous cell carcinoma; chemoimmunotherapy; recurrent/metastatic; treatment related adverse events.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-2025-782/coif). J.C.B. is a co-inventor of a patent pending related to HPV ctDNA assay technology, unrelated to current work. P.L.S. reports having previously served on clinical advisory boards for: CDR-Life, Elevar Therapeutics, Geovax Labs, Prelude Therapeutics, Remix Therapeutics, Astellas/Seagen, and Regeneron; research funding from Ascentage Pharma Group (Institutional), and Summitt Therapeutics (Institutional); and being a co-inventor of a patent pending related to HPV ctDNA assay technology, and none of the above relates to the current work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Barsouk A, Aluru JS, Rawla P, et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel) 2023;11:42. 10.3390/medsci11020042 - DOI - PMC - PubMed
    1. Fong PY, Loh TKS, Shen L, et al. Patterns of recurrence in HNSCC patients treated definitively with upfront surgery, chemoradiation. Eur Arch Otorhinolaryngol 2024;281:2645-53. 10.1007/s00405-024-08556-6 - DOI - PubMed
    1. Leeman JE, Li JG, Pei X, et al. Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. JAMA Oncol 2017;3:1487-94. 10.1001/jamaoncol.2017.0973 - DOI - PMC - PubMed
    1. Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2023;41:790-802. - PMC - PubMed
    1. Sun L, Cohen RB, Dimitrios Colevas A. Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Oral Oncol 2024;158:106997. 10.1016/j.oraloncology.2024.106997 - DOI - PubMed

LinkOut - more resources